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Children with developmental delay or mental retardation (DD/MR) are commonly 
en countered in child neurology clinics, and establishing an etiologic diagnosis is a 
challenge for child neurologists. Among the etiologies, chromosomal imbalance is one 
of the most important causes. However, many of these chromosomal imbalances are 
submicroscopic and cannot be detected by conventional cytogenetic methods. 
Microarray-based comparative genomic hybridization (array CGH) is considered to 
be superior in the investigation of chromosomal deletions or duplications in children 
with DD/MR, and has been demonstrated to improve the diagnostic detection rate 
for these small chromosomal abnormalities. Here, we review the recent studies of 
array CGH in the evaluation of patients with idiopathic DD/MR.
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1. Introduction
Mental retardation (MR) is a condition of arrested or 
incomplete development of the brain with the onset 
occurring before 18 years or age, and is estimated 
to affect 2−3% of the population.1,2 The term devel-
opmental delay (DD), often used in children before 
5 years of age, can involve motor function, cognitive 
ability, language or combinations. MR may become 
evident during infancy or early childhood as devel-
opmental delay, but it is best diagnosed during 
school years.
DD is a common problem in child health and 
a frequent reason for referral to a child neurolo-
gist. However, in a large number of these patients, 
the etiology is unknown. Causes of DD/MR include 
premature birth, genetic and heredity disorders 
and infections. For child neurologists, determining 
whether DD/MR is associated with multiple congen-
ital anomalies and/or dysmorphic features can be 
helpful and guide the selection of diagnostic testing.
Genetic abnormalities are the most common 
iden tifiable cause of DD/MR.3 The traditional study 
of human chromosomes with banding techniques 
can discover large-scale genomic changes and has 
been an important diagnostic tool in identification 
of causes of DD/MR. However, conventional cytoge-
netic analysis cannot reliably detect rearrangements 
of genomic segments smaller than 3−5 million base 
pairs (Mb).4 Fortunately, array-based comparative 
genomic hybridization (array CGH) analysis devel-
opment allows for detection of submicroscopic de-
letions or duplications which cannot be detected by 
conventional cytogenetic methods. Detection rates 
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for chromosome abnormalities with array CGH range 
from 5−17% in individuals with normal results from 
prior routine cytogenetic testing.4
Here, we review recent advances in research 
and diagnostic application of array CGH in the eval-
uation of patients with idiopathic DD/MR.
2. Array CGH
Array CGH uses cloned DNA fragments as a probe 
during hybridization to replace the metaphase chro-
mosomes used in conventional CGH. Metaphase CGH 
uses hybridization to metaphase chromosomes to 
screen the whole genome with an average resolution 
of > 2 Mb. The detection of submicroscopic imbalances 
has been achieved by the replacement of metaphase 
chromosomes with arrayed DNA fragments immobi-
lized on glass slides.3,5 Formerly, bacterial artificial 
chromosomes (BACs) or P1-derived artificial chro-
mosome (PAC) clones ranging in size from 75 to 200 Kb 
were used as the probe DNA.6−8 This method offers 
greater sensitivity and resolution than conventional 
CGH in detecting copy number changes. The level 
of the resolution of array CGH depends on the size 
of and distance between the arrayed interrogating 
probes. Currently, synthetic oligonucleotides, rang-
ing in size from 25−85 bp, are used for high-density 
array CGH. The oligo-array CGH has proven to be a 
powerful and promising method that is revolution-
izing cytogenetic diagnosis.9 Recently, screening 
large patient cohorts with DD/MR by array CGH has 
led to the characterization of several novel micro-
deletion and microduplication syndromes. These 
novel syndromes have been reviewed by Slavotinek.10 
An example of array CGH using oligonucleotides to 
detect a 22q11.2 deletion is shown in Figure 1.
3.  Cytogenetic Evaluation in 
Children with DD/MR
Cytogenetic evaluation is an important part of the 
in vestigation of causes of congenital anomalies, DD/
MR or other developmental disabilities. Based on a 
literature review, the mean yield of chromosome 
aberration is 9.5% in MR.11 G-banding can discover 
numerical and large-scale chromosomal abnormal-
ities. For clinical settings, band karyotyping should 
be the essential and initial diagnostic tool to eval-
uate children with DD/MR. However, G-banding is 
not always sufficient to characterize complex and 
subtle chromo somal abnormalities. Further analy-
sis using high-resolution G-banding and fluores-
cence in-situ hybridization (FISH) should be considered 
consequently when particular syndromes or aberrant 
karyotypes are suspected. Because the ends of chro-
mosomes lack distinctive G-bands, it is difficult to 
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Figure 1 Chromosomal deletion of 22q11.2 shown by CGH analytics version 3.5 (Agilent), in the Chromosome view (left) 
and the Gene view (right). The deletion region of 22q11.2 is shown in Chromosome view (arrow), and expanded in Gene 
view. Vertical axis indicates chromosomal physical locus, and horizontal axis indicates log ratio of sample intensity. 
Plus and minus indicate gain and loss of genomic copy numbers, respectively. In the Gene view, dots indicate locus 
and the log ratio of those intensities, and alphabetic characters indicate location of genes and copy number variations.
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see small rearrangements in these regions in routine 
karyotype analysis and sometimes even at higher 
resolution (850-band). However, it is estimated that 
approximately 5% of unexplained cases of MR/DD 
can be attributed to alterations of the subtelom-
eric regions.12,13 If chromosome analysis is normal at 
550-band resolution, subtelomeric FISH testing may 
be considered.14 Diagnosis of DD/MR has been im-
proved by the use of subtelomeric FISH over the past 
few years.
In cases with no abnormality of karyotyping and 
fragile-X DNA analysis, array CGH is indicated.14 Array 
CGH can detect subtle chromosome aberrations and 
has been demonstrated to improve the diagnostic 
detection rate of these small chromosomal abnor-
malities. Array CGH is superior to conventional cyto-
genetic analysis for the investigation of chromosomal 
aberrations in children with DD/MR. In the individ-
ual with nonspecific DD/MR, array CGH may be used 
in conjunction with routine cytogenetics to replace 
the locus-specific and/or subtelomeric FISH.15 The 
flow chart of cytogenetic tests selected for the eval-
uation of DD/MR is shown in Figure 2.
The estimated detection ratio of genomic abnor-
malities in infants and children with multiple con-
genital anomalies (MCA) and/or DD/MR is 3−5% by 
banded karyotype, another 5−6% by subtelomeric 
FISH, and the other 4−7% by array CGH (higher for 
tiling-paths than for targeted arrays), finally reach-
ing to 12−18% by use of all analyses.3
4. Array CGH Studies in DD/MR
We review seven studies performing array CGH in 
patients with idiopathic DD/MR and summarize the 
results in Table 1.16−22 Six reports used BAC arrays at 
approximately 1-Mb intervals and one report used an 
oligonucleotide array at approximately 6-kb intervals 
across the genome. Since microarray analysis can un-
cover gains and losses in regions of the genome that 
have unclear clinical significance, some of these may 
be benign copy number variants (CNVs).23 Interpre-
tation of copy number variations as being causa-
tive of the disabilities is complex, but a useful and 
widely used standard is to presume that de novo 
gains and losses are causative. Interpretation is diffi-
cult when parental samples are unavailable, or when 
gains or losses are familial.3 We conclude from the 
data in Table that a causative genetic abnormality 
was detected in about 11.7% of cases, with a range 
of 6.4 to 17%. These detection rates are affected 
by the patient selection because patients included 
have varying prior diagnostic studies and a varying 
range of phenotypes. The detection rate of genomic 
rearrangements in patients with DD/MR is higher 
when DD/MR is combined with the malformations or 
dysmorphic features and severe retardation. However, 
an overall estimate might be that array CGH with 
1-Mb resolution can detect causative changes in 10−
15% of patients with idiopathic DD/MR and a normal 
banded karyotype.3 These genomic abnormalities 
are mainly interstitial deletions and duplications.
Conclusions
In summary, recent studies have demonstrated that 
array CGH is a powerful and efficient method for 
diagnosis and research of DD/MR. Array CGH has a 
greater sensitivity than high-resolution karyotyping 
and can target more loci than FISH and in a cost-
effective manner. This technological advance in cy-
togenetic testing has increased the chance of a 
positive diagnosis for patients with DD/MR and their 
families. Clarification of the genetic abnormalities 
de tected by array CGH allows for family counseling 
and prenatal diagnosis. In addition, it can help 
Developmental delay/mental
retardation and/or dysmorphism
G–banding
FISH
Suspicious known syndrome
Subtelomeric FISH
Array CGH
High–resolution banding
Suspicious unknown syndromeAbnormality detection (−)
Abnormality detection (−)
Figure 2 Cytogenetic test selection used in the evaluation of children with DD/MR.
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identify the candidate gene regions/genes under-
lying the DD/MR.
In the future, reduction of costs for array CGH 
will open the way for applying this method as a first-
tier test in the context of children with idiopathic 
DD/MR.
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